Advisory Research’s Ginkgo Bioworks DNA Stock Holding History

Advisory Research’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,729	Closed	-$715K	–	378
2022 Q3	$715K	Buy	5,729 +1,006	+21%	+$120K	0.07%	196
2022 Q2	$450K	Buy	4,723 +2,268	+92%	+$277K	0.04%	237
2022 Q1	$396K	Sell	2,455 -293	-11%	-$57K	0.03%	275
2021 Q4	$913K	Buy	2,748 +911	+50%	+$433K	0.07%	205
2021 Q3	$852K	Buy	+1,837	New	+$894K	0.05%	214

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Advisory Research's DNA Position: Q4 2022 in Review

Advisory Research sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 5,729 shares — an estimated $715K sold.

Advisory Research first reported a position in DNA in Q3 2021 and held it in 5 quarters. The position peaked at $913K in Q4 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

Advisory Research reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
Advisory Research sold 5,729 Ginkgo Bioworks shares in Q4 2022, an estimated $715K.
Advisory Research first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 5 quarters.
Advisory Research's Ginkgo Bioworks position peaked at $913K in Q4 2021.
320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.